ARAP3 and early-onset autosomal dominant Alzheimer disease: As actin disruption can further contribute to degeneration of neurites and synaptic dysfunctions in AD36,40,41, the Aβ-SHIP2-ARAP3-RhoA signaling pathway can be considered as new therapeutic candidates for Alzheimer’s disease.